Disease Information

General Information of the Disease (ID: DIS00537)

• Name: Breast invasive carcinoma
• ICD: ICD-11: 2C61

Type(s) of Resistant Mechanism of This Disease

  MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Drug

Approved Drug(s) 2 drug(s) in total

Everolimus

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Neurofibromin 1 (NF1) [1]

• Metabolic Type: Lipid metabolism
• Sensitive Disease: ER+ breast adenocarcinoma [ICD-11: 2C61.1]
• Sensitive Drug: Everolimus
• Molecule Alteration: Mutation; .
• Experimental Note: Revealed Based on the Cell Line Data
• In Vivo Model: Rat, with ER + MCF7 cell lines; Rats
• Experiment for Molecule Alteration: LC-MS
• Experiment for Drug Resistance: Incucyte proliferation assay
• Mechanism Description: Lastly,NF1deficiency alters the synergy between metabolic inhibitors and traditional targeted inhibitors. This includes increased synergy with inhibitors targeting glycolysis, glutamine metabolism, mitochondrial fatty acid transport, and TG synthesis.

Tamoxifen

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Neurofibromin 1 (NF1) [1]

• Metabolic Type: Lipid metabolism
• Sensitive Disease: ER+ breast adenocarcinoma [ICD-11: 2C61.1]
• Sensitive Drug: Tamoxifen
• Molecule Alteration: Mutation; .
• Experimental Note: Revealed Based on the Cell Line Data
• In Vivo Model: Rat, with ER + MCF7 cell lines; Rats
• Experiment for Molecule Alteration: LC-MS
• Experiment for Drug Resistance: Incucyte proliferation assay
• Mechanism Description: Lastly,NF1deficiency alters the synergy between metabolic inhibitors and traditional targeted inhibitors. This includes increased synergy with inhibitors targeting glycolysis, glutamine metabolism, mitochondrial fatty acid transport, and TG synthesis.

Clinical Trial Drug(s) 2 drug(s) in total

Cobimetinib

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Neurofibromin 1 (NF1) [1]

• Metabolic Type: Lipid metabolism
• Sensitive Disease: ER+ breast adenocarcinoma [ICD-11: 2C61.1]
• Sensitive Drug: Cobimetinib
• Molecule Alteration: Mutation; .
• Experimental Note: Revealed Based on the Cell Line Data
• In Vivo Model: Rat, with ER + MCF7 cell lines; Rats
• Experiment for Molecule Alteration: LC-MS
• Experiment for Drug Resistance: Incucyte proliferation assay
• Mechanism Description: Lastly,NF1deficiency alters the synergy between metabolic inhibitors and traditional targeted inhibitors. This includes increased synergy with inhibitors targeting glycolysis, glutamine metabolism, mitochondrial fatty acid transport, and TG synthesis.

2DG

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Neurofibromin 1 (NF1) [1]

• Metabolic Type: Lipid metabolism
• Sensitive Disease: ER+ breast adenocarcinoma [ICD-11: 2C61.1]
• Sensitive Drug: 2DG
• Molecule Alteration: Mutation; .
• Experimental Note: Revealed Based on the Cell Line Data
• In Vivo Model: Rat, with ER + MCF7 cell lines; Rats
• Experiment for Molecule Alteration: LC-MS
• Experiment for Drug Resistance: Incucyte proliferation assay
• Mechanism Description: Lastly,NF1deficiency alters the synergy between metabolic inhibitors and traditional targeted inhibitors. This includes increased synergy with inhibitors targeting glycolysis, glutamine metabolism, mitochondrial fatty acid transport, and TG synthesis.

Discontinued Drug(s) 2 drug(s) in total

Etomoxir

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Neurofibromin 1 (NF1) [1]

• Metabolic Type: Lipid metabolism
• Sensitive Disease: ER+ breast adenocarcinoma [ICD-11: 2C61.1]
• Sensitive Drug: Etomoxir
• Molecule Alteration: Mutation; .
• Experimental Note: Revealed Based on the Cell Line Data
• In Vivo Model: Rat, with ER + MCF7 cell lines; Rats
• Experiment for Molecule Alteration: LC-MS
• Experiment for Drug Resistance: Incucyte proliferation assay
• Mechanism Description: Lastly,NF1deficiency alters the synergy between metabolic inhibitors and traditional targeted inhibitors. This includes increased synergy with inhibitors targeting glycolysis, glutamine metabolism, mitochondrial fatty acid transport, and TG synthesis.

PF-04620110

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Neurofibromin 1 (NF1) [1]

• Metabolic Type: Lipid metabolism
• Sensitive Disease: ER+ breast adenocarcinoma [ICD-11: 2C61.1]
• Sensitive Drug: PF-04620110
• Molecule Alteration: Mutation; .
• Experimental Note: Revealed Based on the Cell Line Data
• In Vivo Model: Rat, with ER + MCF7 cell lines; Rats
• Experiment for Molecule Alteration: LC-MS
• Experiment for Drug Resistance: Incucyte proliferation assay
• Mechanism Description: Lastly,NF1deficiency alters the synergy between metabolic inhibitors and traditional targeted inhibitors. This includes increased synergy with inhibitors targeting glycolysis, glutamine metabolism, mitochondrial fatty acid transport, and TG synthesis.

Preclinical Drug(s) 2 drug(s) in total

BPTES

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Neurofibromin 1 (NF1) [1]

• Metabolic Type: Lipid metabolism
• Sensitive Disease: ER+ breast adenocarcinoma [ICD-11: 2C61.1]
• Sensitive Drug: BPTES
• Molecule Alteration: Mutation; .
• Experimental Note: Revealed Based on the Cell Line Data
• In Vivo Model: Rat, with ER + MCF7 cell lines; Rats
• Experiment for Molecule Alteration: LC-MS
• Experiment for Drug Resistance: Incucyte proliferation assay
• Mechanism Description: Lastly,NF1deficiency alters the synergy between metabolic inhibitors and traditional targeted inhibitors. This includes increased synergy with inhibitors targeting glycolysis, glutamine metabolism, mitochondrial fatty acid transport, and TG synthesis.

PF-06424439

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Neurofibromin 1 (NF1) [1]

• Metabolic Type: Lipid metabolism
• Sensitive Disease: ER+ breast adenocarcinoma [ICD-11: 2C61.1]
• Sensitive Drug: PF-06424439
• Molecule Alteration: Mutation; .
• Experimental Note: Revealed Based on the Cell Line Data
• In Vivo Model: Rat, with ER + MCF7 cell lines; Rats
• Experiment for Molecule Alteration: LC-MS
• Experiment for Drug Resistance: Incucyte proliferation assay
• Mechanism Description: Lastly,NF1deficiency alters the synergy between metabolic inhibitors and traditional targeted inhibitors. This includes increased synergy with inhibitors targeting glycolysis, glutamine metabolism, mitochondrial fatty acid transport, and TG synthesis.

References

• Ref 1: NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. Mol Metab. 2024 Feb;80:101876.